Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
San Francisco, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Sylmar, CA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Sylmar, CA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Hialeah, FL
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Miami, FL
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
South Miami, FL
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Chicago, IL
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Oak Park, IL
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Oak Park, IL
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Baltimore, MD
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Boston, MA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Emerson, NJ
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Emerson, NJ
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Summit, NJ
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Summit, NJ
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Tom's River, NJ
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Tom's River, NJ
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
New York, NY
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Willoughby, OH
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Willoughby, OH
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Wyomissing, PA
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Dallas, TX
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
Lewisville, TX
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
Lewisville, TX
Click here to add this to my saved trials
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated:  9/22/2015
Clinical Research Facility
mi
from
McAllen, TX
Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers
A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers
Status: Enrolling
Updated: 9/22/2015
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia
Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia
Status: Enrolling
Updated:  9/22/2015
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia
Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia
Status: Enrolling
Updated: 9/22/2015
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
University of Chicago
mi
from
Chicago, IL
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
NorthShore University HealthSystem
mi
from
Evanston, IL
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Capital Federal,
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
A Prospective, Randomized, Controlled, Single-Site Post Marketing Study to Identify & Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
Status: Enrolling
Updated:  9/23/2015
University of Miami
mi
from
Miami, FL
A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
A Prospective, Randomized, Controlled, Single-Site Post Marketing Study to Identify & Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
Status: Enrolling
Updated: 9/23/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Southern California Medical Gastroenterology Group
mi
from
Santa Monica, CA
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Southern California Medical Gastroenterology Group
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Gastroenterology Research of New Orleans
mi
from
Hammond, LA
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Gastroenterology Research of New Orleans
mi
from
Hammond, LA
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr
mi
from
Chevy Chase, MD
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Gastroenterology Research Of San Antonio
mi
from
San Antonio, TX
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Gastroenterology Research Of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Shafran Gasteroenterology Center
mi
from
Winter Park, FL
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Shafran Gasteroenterology Center
mi
from
Winter Park, FL
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Midwest Center for Clinical Research
mi
from
Lees Summit, MO
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Midwest Center for Clinical Research
mi
from
Lees Summit, MO
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Brussel,
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Brussel,
Click here to add this to my saved trials
Yoga for Pain and Opioid Dependence
Yoga for Pain and Opioid Dependence
Status: Enrolling
Updated:  9/23/2015
MRU
mi
from
New Haven, CT
Yoga for Pain and Opioid Dependence
Yoga for Pain and Opioid Dependence
Status: Enrolling
Updated: 9/23/2015
MRU
mi
from
New Haven, CT
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Scripps Clinic
mi
from
La Jolla, CA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Medical Associates Research Group
mi
from
San Diego, CA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Medical Associates Research Group
mi
from
San Diego, CA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Quest Clinical Research
mi
from
San Francisco, CA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Quest Clinical Research
mi
from
San Francisco, CA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
University Of Colorado Denver & Hospital
mi
from
Aurora, CO
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
University Of Colorado Denver & Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Borland-Groover Clinic
mi
from
Jacksonville, FL
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Borland-Groover Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Miami Research Associates
mi
from
South Miami, FL
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Gastrointestinal Specialists of Georgia
mi
from
Marietta, GA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Gastrointestinal Specialists of Georgia
mi
from
Marietta, GA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Kansas City Care Clinic
mi
from
Kansas City, MO
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Kansas City Care Clinic
mi
from
Kansas City, MO
Click here to add this to my saved trials